Fluridil

Male pattern hairloss is associated with Dihydrotesterone or DHT binding to the Androgen (male hormone) Receptor in hair follicles. Current treatments include preventing the creation of DHT (Propecia) and preventing DHT from binding to the receptor (Spironolactone, RU58841). Fluridil may represent a new method of treatment. According to it's maker, Fluridil blocks activity in the Androgen Receptor itself. Fluridil has been approved in the Czech republic and is being used there already for cosmetic use and marketing approval is pending in several other countries.

**Specifics**
Treatment Type	Androgen Receptor Suppression
Availability	Available in Czech Republic, other approvals pending
Clinical Results	No clinical data yet published.
Observed Results	Not yet available to public.
Side Effects	None observed.
Cost	Not Yet Available
Where You Can Get It Online	Not Yet Available